None

Tigermed turns to face global expansion after $80m IPO

The Chinese CRO Hangzhou Tigermed Consulting (Tigermed) has raised $79.8 million through the sale of 13.4 million shares on the ChiNext hi-tech exchange of the Shenzen Stock Exchange. It is thought th...

Chinese CRO Tigermed raises $79.8M in IPO

Chinese CRO Hangzhou Tigermed Consulting Co. Ltd. (SZSE:300347) raised RMB507.6 million ($79.8 million) through the sale of 13.4 million shares at RMB37.88 per share in an IPO on the ChiNext hi-tech e...

Merck contracts clinical trial services from Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting signed a letter of intent with MSD China that calls for Tigermed to provide MSD with clinical trial services for a three-year period, from August 15, 2012 to July 31, 2015...

Tigermed To Provide Merck Clinical Trial Services In China

Hangzhou Tigermed Consulting Co. Ltd. has signed a letter of intent with Merck & Co.

Tigermed To List In China At RMB 37.88

Hangzhou Tigermed Consulting Co. Ltd. will be listed on the Shenzhen Stock Exchange’s Growth Enterprise Market with the stock code 300347 beginning Aug. 17.

Hangzhou Tigermed Consulting announces IPO for $80 million

Hangzhou Tigermed Consulting  staged its IPO on Shenzhen’s ChiNext exchange. The IPO, which constitutes 25% of the company’s outstanding stock, placed 13.40 million shares in investors’ hands a...

Tigermed and MSD China Sign LOI for Clinical Trial Services

Hangzhou Tigermed Consulting, a China CRO, signed a letter of intent with MSD China that calls for Tigermed to provide MSD with clinical trial services for a three-year period, from August 15, 2012...

Tigermed Completes $80 Million IPO on the ChiNext Exchange

Hangzhou Tigermed Consulting Co., a clinical-stage CRO, staged its IPO today on Shenzhen’s ChiNext exchange. The IPO, which constitutes 25% of the company’s outstanding stock, placed 13.4...

None